Concern over EU guidance on NIMP clinical trials dossiers
This article was originally published in SRA
Executive Summary
The European Commission's draft guideline explaining dossier requirements for clinical trials involving non-investigational products or NIMPs has been largely welcomed by stakeholders, as no such guidance previously existed1-3. There are, however, concerns that the document's strict interpretation could lead to problems.